In 2023, obstructive airway diseases medicine sales in Canada stood at a certain level, with forecasts from 2024 to 2028 indicating a gradual increase in per capita sales, from 41 USD in 2024 to 41.6 USD in 2028. Year-on-year percentage growth reveals a stable but modest upward trend, with annual growth rates slowly declining, suggesting market maturity. The compound annual growth rate over this period reflects a low, steady increase in demand, reflective of consistent market expansion.
Future trends to watch for include innovations in treatment methods, potential changes in healthcare policy, or the introduction of new competitor products, which could significantly impact these forecasts.
